

Luke S Howard

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8532347/luke-s-howard-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106
papers

7,589
citations

40
h-index

86
g-index

121
ext. papers

9,378
ext. citations

9
avg, IF

5.5
L-index

#	Paper	IF	Citations
106	ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. <i>ERJ Open Research</i> , 2022 , 8, 00665-2021	3.5	0
105	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. <i>Nature Communications</i> , 2021 , 12, 7104	17.4	1
104	TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021 , 11, 20458940211057071	2.7	3
103	Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement. <i>British Journal of Anaesthesia</i> , 2021 , 126, 774-790	5.4	6
102	A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. <i>EBioMedicine</i> , 2021 , 69, 103444	8.8	5
101	EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	9
100	Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	9
99	Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 107-116	35.1	47
98	Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. <i>European Heart Journal</i> , 2021 , 42, 1866-1878	9.5	112
97	Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH. <i>European Respiratory Journal</i> , 2021 ,	13.6	6
96	Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy. <i>Pulmonary Circulation</i> , 2021 , 11, 20458940211052823	2.7	1
95	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 586-594	10.2	14
94	Whole-genome sequencing of patients with rare diseases in a national health system. <i>Nature</i> , 2020 , 583, 96-102	50.4	139
93	Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure. <i>Circulation</i> , 2020 , 141, 678-693	16.7	39
92	Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1): Multicenter, Early Feasibility Study. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 989-999	5	15
91	Global Right Heart Assessment with Speckle-Tracking Imaging Improves the Risk Prediction of a Validated Scoring System in Pulmonary Arterial Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2020 , 33, 1334-1344.e2	5.8	5
90	Bayesian Inference Associates Rare Variants with Specific Phenotypes in Pulmonary Arterial Hypertension. <i>Circulation Genomic and Precision Medicine</i> , 2020 ,	5.2	9

89	Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype?. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020914851	2.7	8
88	The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	16
87	Acute pulmonary embolism. <i>Clinical Medicine</i> , 2019 , 19, 243-247	1.9	10
86	Human PAH is characterized by a pattern of lipid-related insulin resistance. <i>JCI Insight</i> , 2019 , 4,	9.9	36
85	Management of pulmonary arterial hypertension in patients aged over 65 years. <i>European Heart Journal Supplements</i> , 2019 , 21, K29-K36	1.5	5
84	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 227-238	35.1	55
83	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	63
82	Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension. <i>Thorax</i> , 2019 , 74, 380-389	7.3	16
81	The importance of patient perspectives in pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	50
80	Lung Function, Inflammation, and Endothelin-1 in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	13
79	Power of resting echocardiographic measurements to classify pulmonary hypertension patients according to European society of cardiology exercise testing risk stratification cut-offs. <i>International Journal of Cardiology</i> , 2018 , 257, 291-297	3.2	5
78	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. <i>Nature Communications</i> , 2018 , 9, 1416	17.4	182
77	Right ventriculo-arterial uncoupling and impaired contractile reserve in obese patients with unexplained exercise intolerance. <i>European Journal of Applied Physiology</i> , 2018 , 118, 1415-1426	3.4	3
76	Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?. <i>Expert Review of Respiratory Medicine</i> , 2018 , 12, 387-402	3.8	1
75	Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. <i>Echo Research and Practice</i> , 2018 , 5, G11-G24	2	86
74	British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism. <i>BMJ Open Respiratory Research</i> , 2018 , 5, e000281	5.6	9
73	BTS guidelines for the initial outpatient management of pulmonary embolism: there's no place like home. <i>Thorax</i> , 2018 , 73, 607-608	7.3	4
72	Resting right ventricular function is associated with exercise performance in PAH, but not in CTEPH. <i>European Heart Journal Cardiovascular Imaging</i> , 2018 , 19, 185-192	4.1	10

71	Echocardiographic Screening for Pulmonary Hypertension in Congenital Heart Disease: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2778-2788	15.1	22
70	Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. <i>Journal of Heart and Lung Transplantation</i> , 2017 , 36, 770-779	5.8	47
69	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 717-726	35.1	62
68	Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	144
67	Exertional dyspnoea in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2017 , 26,	9.8	17
66	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 785-794	35.1	133
65	The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. <i>Thorax</i> , 2017 , 72, 1035-1045	7.3	20
64	Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017 , 135, 460-475	16.7	96
63	An official European Respiratory Society statement: pulmonary haemodynamics during exercise. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	124
62	125 Deterioration of Right Ventricular Function on Exercise Detected by Exercise Cardiac Magnetic Resonance Imaging in Patients with Pulmonary Arterial Hypertension. <i>Heart</i> , 2016 , 102, A88-A89	5.1	
61	Risk Stratification of Patients With Acute Symptomatic Pulmonary Embolism Based on Presence or Absence of Lower Extremity DVT: Systematic Review and Meta-analysis. <i>Chest</i> , 2016 , 149, 192-200	5.3	55
60	Patient engagement and self-management in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2016 , 25, 399-407	9.8	31
59	Exercise physiological responses to drug treatments in chronic thromboembolic pulmonary hypertension. <i>Journal of Applied Physiology</i> , 2016 , 121, 623-8	3.7	17
58	Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort. <i>Circulation</i> , 2016 , 133, 1761-71	16.7	203
57	Developments in the management and treatment of pulmonary embolism. <i>European Respiratory Review</i> , 2015 , 24, 484-97	9.8	17
56	Relating oxygen partial pressure, saturation and content: the haemoglobin-oxygen dissociation curve. <i>Breathe</i> , 2015 , 11, 194-201	1.8	159
55	Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency. <i>Pulmonary Circulation</i> , 2015 , 5, 466-72	2.7	60
54	Connective tissue disease-associated pulmonary arterial hypertension. <i>F1000prime Reports</i> , 2015 , 7, 06		32

53	Pulmonary arterial hypertension: the burden of disease and impact on quality of life. <i>European Respiratory Review</i> , 2015 , 24, 621-9	9.8	91
52	Left main bronchus compression due to main pulmonary artery dilatation in pulmonary hypertension: two case reports. <i>Pulmonary Circulation</i> , 2015 , 5, 723-5	2.7	7
51	Pulmonary arterial hypertension exacerbated by ruxolitinib. <i>Haematologica</i> , 2015 , 100, e244-5	6.6	25
50	Cardiopulmonary exercise testing demonstrates maintenance of exercise capacity in patients with hypoxemia and pulmonary arteriovenous malformations. <i>Chest</i> , 2014 , 146, 709-718	5.3	21
49	Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. <i>Rheumatology</i> , 2014 , 53, 285-92	3.9	37
48	Physicians' and patients' expectations of therapies for pulmonary arterial hypertension: where do they meet?. <i>European Respiratory Review</i> , 2014 , 23, 458-68	9.8	9
47	Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. <i>Pulmonary Circulation</i> , 2014 , 4, 669-78	2.7	14
46	Aberrant chloride intracellular channel 4 expression contributes to endothelial dysfunction in pulmonary arterial hypertension. <i>Circulation</i> , 2014 , 129, 1770-80	16.7	35
45	NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing. <i>Thorax</i> , 2013 , 68, 391-3	7.3	40
44	Treatment goals of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2013 , 62, D73-81	15.1	207
43	Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 294-302	10.2	126
42	Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives. <i>European Respiratory Review</i> , 2013 , 22, 535-42	9.8	85
41	Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. <i>Circulation</i> , 2013 , 128, 1214-24	16.7	86
40	Authors' response to: How should we best determine the need for in-flight oxygen in patients with pulmonary arterial hypertension. <i>Thorax</i> , 2013 , 68, 680.2-681	7.3	
39	The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom. <i>British Journal of Haematology</i> , 2013 , 162, 400-8	4.5	26
38	Pulmonary vascular disease: pulmonary thromboembolism and pulmonary hypertension. <i>Medicine</i> , 2012 , 40, 214-220	0.6	1
37	Morphologic and functional remodeling of the right ventricle in pulmonary hypertension by real time three dimensional echocardiography. <i>American Journal of Cardiology</i> , 2012 , 109, 906-13	3	41
36	Cardiopulmonary exercise testing. <i>Pulmonary Medicine</i> , 2012 , 2012, 564134	5.3	

35	An audit of hypoxaemia, hyperoxaemia, hypercapnia and acidosis in blood gas specimens. <i>European Respiratory Journal</i> , 2012 , 39, 219-21	13.6	4
34	Echocardiographic assessment of pulmonary hypertension: standard operating procedure. <i>European Respiratory Review</i> , 2012 , 21, 239-48	9.8	110
33	Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 790-6	10.2	370
32	Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 300-9	15.1	166
31	British Thoracic Society emergency oxygen audits. <i>Thorax</i> , 2011 , 66, 734-5	7.3	32
30	Right atrial flutter isthmus ablation is feasible and results in acute clinical improvement in patients with persistent atrial flutter and severe pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2011 , 149, 279-280	3.2	29
29	Outpatient management of pulmonary embolism. <i>Lancet, The</i> , 2011 , 378, 5-6	4.0	5
28	Differences in ventilatory inefficiency between pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Chest</i> , 2011 , 140, 1284-1291	5.3	79
27	Combination therapy in pulmonary arterial hypertension: do we have the right strategy?. <i>Expert Review of Respiratory Medicine</i> , 2011 , 5, 191-205	3.8	5
26	How to assess the dangers of hyperoxemia: methodological issues. <i>Critical Care</i> , 2011 , 15, 435; author reply 435	10.8	2
25	Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. <i>European Respiratory Journal</i> , 2011 , 37, 813-22	13.6	75
24	Rebound hypoxaemia after administration of oxygen in an acute exacerbation of chronic obstructive pulmonary disease. <i>BMJ, The</i> , 2011 , 342, d1557	5.9	14
23	Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. <i>European Respiratory Journal</i> , 2011 , 38, 1453-60	13.6	78
22	Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease. <i>European Respiratory Review</i> , 2011 , 20, 236-42	9.8	52
21	Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. <i>Heart</i> , 2011 , 97, 1054-60	5.1	125
20	Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. <i>Experimental Lung Research</i> , 2011 , 37, 26-34	2.3	42
19	Right ventricular function in patients with pulmonary hypertension; the value of myocardial performance index measured by tissue Doppler imaging. <i>European Journal of Echocardiography</i> , 2010 , 11, 719-24		22
18	Reduced confounding by impaired ventilatory function with oxygen uptake efficiency slope and VE/VCO2 slope rather than peak oxygen consumption to assess exercise physiology in suspected heart failure. <i>Congestive Heart Failure</i> , 2010 , 16, 259-64		3

17	Oxygen in myocardial infarction. Maintain normoxaemia until more evidence is available. <i>BMJ, The</i> , 2010 , 341, c3715	5.9	4
16	Simvastatin as a treatment for pulmonary hypertension trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 181, 1106-13	10.2	93
15	Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 180, 780-7	10.2	171
14	Oxygen therapy. <i>Clinical Medicine</i> , 2009 , 9, 156-9	1.9	3
13	Response to Letter Regarding Article, "Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension" <i>Circulation</i> , 2009 , 119,	16.7	1
12	Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). <i>European Heart Journal</i> , 2009 , 30, 2493-537	9.5	2531
11	Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. <i>American Journal of Cardiovascular Drugs</i> , 2008 , 8, 171-85	4	39
10	Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. <i>Circulation</i> , 2008 , 117, 3020-30	16.7	184
9	Pulmonary veno-occlusive disease presenting with recurrent pulmonary oedema and the use of nitric oxide to predict response to sildenafil. <i>Thorax</i> , 2008 , 63, 933-4	7.3	26
8	Use of vasopressin after Caesarean section in idiopathic pulmonary arterial hypertension. <i>British Journal of Anaesthesia</i> , 2007 , 99, 552-5	5.4	57
7	Emerging therapies for pulmonary arterial hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 803-18	5.9	12
6	Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate. <i>Chest</i> , 2006 , 129, 1718-21	5.3	34
5	Large granular lymphocyte leukaemia: a curable form of pulmonary arterial hypertension [corrected]. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2005 , 66, 364-5	0.8	2
4	Initial oxygen management in patients with an exacerbation of chronic obstructive pulmonary disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005 , 98, 499-504	2.7	35
3	New therapeutic agents for pulmonary vascular disease. <i>Paediatric Respiratory Reviews</i> , 2005 , 6, 285-91	4.8	19
2	Microbiological profile of community-acquired pneumonia in adults over the last 20 years. <i>Journal of Infection</i> , 2005 , 50, 107-13	18.9	47
1	Physical, cognitive and mental health impacts of COVID-19 following hospitalisation multi-centre prospective cohort study		17